About 7,493 results

ALLMedicine™ Hypercalcemia Center

Research & Reviews  1,884 results

Osteoarticular manifestation of acute lymphoblastic leukemia in adults: a literature re...
Clinical Rheumatology; Slouma M, Hannech E et. al.

Dec 2nd, 2022 - Osteoarticular manifestations such as arthritis and bone pain are scarce among adults with acute lymphoblastic leukemia (ALL). We present a systematic review of osteoarticular first clinical manifestation related to ALL in adults, and we report a ...

CCL18 promotes migration and invasion of multiple myeloma cells and is associated with ...
Carcinogenesis Qiao B, Chen L et. al.

Dec 2nd, 2022 - CCL18 has recently been implicated in malignancies and is increasingly mentioned as a potential tumoral biomarker and furtherly a molecular target for therapeutic intervention, but its expression and clinical significance in multiple myeloma have ...

The potential link between Covid-19 and multiple myeloma: A new saga.
Immunity, Inflammation and Disease; Al-Kuraishy HM, Al-Gareeb AI et. al.

Nov 30th, 2022 - Covid-19 is considered a primary respiratory disease-causing viral pneumonia and, in severe cases, leads to acute lung injury and acute respiratory distress syndrome (ARDS). In addition, though, extra-pulmonary manifestations of Covid-19 have been...

Impact of intravenous calcium with diltiazem for atrial fibrillation/flutter in the eme...
The American Journal of Emergency Medicine; Rossi N, Allen B et. al.

Nov 29th, 2022 - The purpose of this study was to evaluate the effect of early intravenous (IV) calcium on systolic blood pressure (SBP) when administered with IV diltiazem in subjects with atrial fibrillation (AF) or flutter (AFL) with rapid ventricular response ...

Management of cancer pain due to bone metastasis.
Journal of Bone and Mineral Metabolism; Takei D, Tagami K

Nov 24th, 2022 - Bone metastases frequently occur in patients with cancer. Skeletal-related events (SREs), including pain, impaired mobility, hypercalcemia, pathological fracture, spinal cord and nerve root compression, and bone marrow infiltration, can decrease t...

see more →

Guidelines  4 results

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

SEOM guidelines on hydroelectrolytic disorders.
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

Vitamin D Toxicity - StatPearls
StatPearls Asif A, Farooq N.

Vitamin D is a fat-soluble vitamin that is found in some animal food products and is also synthesized in the human body via exposure to the sun. Toxicity of vitamin D leads to hypercalcemia and imbalance in the regulation of bone metabolism; the r...

see more →

Drugs  623 results see all →

Clinicaltrials.gov  161 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Oct 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Studies of Inherited Diseases of Metabolism

Oct 14th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients

Oct 13th, 2022 - Chronic kidney disease-mineral and bone disorder (CKD-MBD) is characterized by progressive loss of renal function as well as dysregulation of mineral and bone metabolism, leading frequently to hyperphosphatemia. Multiple studies have consistently ...

Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma

Oct 12th, 2022 - Laryngeal squamous cell carcinoma (LSCC) is the second most common primary malignant tumor of the respiratory tract after lung cancer and the second most common primary epithelial malignant tumor of the head and neck. The age of onset of LSCC is m...

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Oct 7th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or t...

see more →

News  310 results

FGFR2 Inhibitor RLY-4008 Appears Durable, Tolerable in Cholangiocarcinoma

Nov 23rd, 2022 - RLY-4008, a highly selective FGFR2 inhibitor, has demonstrated promising efficacy in patients with FGFR2-altered cholangiocarcinoma, while sparing patients the adverse effects (AEs) typically seen with pan-FGFR inhibitors, according to Suneel Kama...

FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

Oct 28th, 2022 - The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor (PI), an immunomodulat...

Multiple Myeloma: Disparities in Time to Diagnosis

Oct 11th, 2022 - Transcript: Joseph Mikhael, MD: Let's move then into thinking about some of these now evident disparities. We've tried to think about the why. There's the biological phenomenon, there's the societal phenomenon which we're just hitting the top of ...

Societal Determinants of Health in Multiple Myeloma

Oct 11th, 2022 - Transcript: Joseph Mikhael, MD: Excellent, that's helpful. On the subject of trying to figure out why and that is obviously this first module that we're looking at, Craig I'm going to turn to you for a moment because as a scientists we think mayb...

Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma

Aug 18th, 2022 - Brea Lipe, MD: Hello and welcome to this OncLive® My Treatment Approach program titled, "Recent Advances in the Treatment of Multiple Myeloma at First Relapse." I am Brea Lipe, and I'm the associate professor at the department of medicine at the U...

see more →

Patient Education  15 results see all →